Pear Therapeutics to Participate in 9th Annual SVB Leerink Global Healthcare Conference
Boston, February 12, 2020 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26 at the Lotte New York Palace.
About Pear Therapeutics
Pear Therapeutics, Inc. is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, for the treatment of Substance Use Disorder, was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at www.peartherapeutics.com.
Media and Investors:
Director, Corporate Communications